Tag: year

Eight-time Grand Prix winner, Daniel Ricciardo shifts his focus to engaging fans through a brand-new tailgating venture

WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on June 16, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 112,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

CALGARY, Alberta and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Magnetic North Acquisition Corp. (TSXV: MNC; MNC.PR.A) (“Magnetic North” or the “Company”) is providing this bi-weekly update on the status of the management cease trade order granted on May 9, 2025 (the “MCTO”) by its principal regulator, the Alberta Securities Commission (“ASC”) , under National Policy 12-203 - Management Cease Trade Orders (“NP 12-203”), following the Company’s announcement on May 8, 2025 (the “Default Announcement”) that it was unable to file its audited annual financial statements, ‎management’s discussion and analysis and related certifications for the year ended December ‎‎31, 2024 (the “Documents”) ‎on or before April 30, 2025, as required under applicable securities laws. The Company does not expect to file the Documents by the MCTO’s deadline of June 30, 2025. See (ii) below.

ROSEMONT, Ill., June 20, 2025 (GLOBE NEWSWIRE) -- Wintrust Financial Corporation ("Wintrust") (Nasdaq: WTFC) today announced it will release second quarter and year-to-date 2025 earnings results after the market closes on Monday, July 21, 2025 and host a conference call on Tuesday, July 22, 2025 at 10:00 a.m. (CDT).

Virtual webinar on June 23, 2025 at 8:00 am ET

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation